Abstract | BACKGROUND AND PURPOSE: METHODS: Bone marrow-derived EPCs were injected intra-arterially into db/db mice after ischemic stroke induction. RWJ 67657 (RWJ), a p38 mitogen-activated protein kinase inhibitor, was administered orally for 7 consecutive days, with the first dose given 30 minutes before stroke induction. Functional outcome was determined at days 0, 1, 7, 14, and 21. Angiogenesis, neurogenesis, infarct volume, and Western blotting assays were performed on day 7, and white matter remodeling was determined on day 14. RESULTS: CONCLUSIONS:
|
Authors | Ying-Ying Bai, Lishan Wang, Di Chang, Zhen Zhao, Chun-Qiang Lu, Guozheng Wang, Shenghong Ju |
Journal | Stroke
(Stroke)
Vol. 46
Issue 7
Pg. 1938-46
(Jul 2015)
ISSN: 1524-4628 [Electronic] United States |
PMID | 26045601
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 American Heart Association, Inc. |
Chemical References |
- Imidazoles
- Pyridines
- RWJ 67657
- Mitogen-Activated Protein Kinases
|
Topics |
- Animals
- Brain Ischemia
(pathology, therapy)
- Diabetes Mellitus, Experimental
(pathology, therapy)
- Disease Models, Animal
- Endothelial Progenitor Cells
(transplantation)
- Imidazoles
(administration & dosage)
- Male
- Mice
- Mitogen-Activated Protein Kinases
(antagonists & inhibitors)
- Pyridines
(administration & dosage)
- Stem Cell Transplantation
(methods)
- Stroke
(pathology, therapy)
- Treatment Outcome
|